Entrada Therapeutics, Inc. Common Stock
Symbol: TRDA (NASDAQ)
Company Description:
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
- Today's Open: $6.32
- Today's High: $6.465
- Today's Low: $6.28
- Today's Volume: 141.73K
- Yesterday Close: $6.31
- Yesterday High: $6.49
- Yesterday Low: $6.15
- Yesterday Volume: 226.28K
- Last Min Volume: 1
- Last Min High: $6.4
- Last Min Low: $6.4
- Last Min VWAP: $6.4
- Name: Entrada Therapeutics, Inc. Common Stock
- Website: https://www.entradatx.com
- Listed Date: 2021-10-29
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001689375
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $241.92M
- Round Lot: 100
- Outstanding Shares: 38.04M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-04 | 4 | View |
2025-09-04 | 4 | View |
2025-09-04 | 4 | View |
2025-09-04 | 4 | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-06 | 10-Q | View |
2025-08-06 | 8-K | View |
2025-07-11 | 4 | View |
2025-07-11 | 4 | View |
2025-07-09 | 144 | View |
2025-07-09 | 144 | View |
2025-07-01 | 4 | View |
2025-07-01 | 4 | View |
2025-07-01 | 144 | View |
2025-07-01 | 144 | View |
2025-06-30 | 144 | View |
2025-06-30 | 144 | View |
2025-06-27 | 144 | View |
2025-06-27 | 144 | View |